Topical eye serum compositions, methods or preparing, and methods of use
Methods for preparing an eye serum formulation are disclosed. The methods include electrolyzing a saline solution having a salt concentration between about 0.01% and about 1.0% by weight using a voltage between about 0 V and about 30 V across an inert anode and a spaced apart inert cathode to generate a target mixture of chemically reduced and oxidized molecules within the saline solution, mirroring the target mixture of chemically reduced and oxidized species in the electrolyzed saline solution to the reduced species and reactive oxygen species found in a known biological system, adding a rheology modifier, adding a buffering agent, and adding a silicone oil. The target mixture of chemically reduced and oxidized molecules comprises one or more of hypochlorous acid, hypochlorites, dissolved oxygen, chlorine, hydrogen gas, hydrogen peroxide, hydrogen ions, hypochloride, superoxides, ozone, activated hydrogen ions, chloride ions, hydroxides, singlet oxygen, *OCl, and *HO—.
1. A topical eye serum formulation for application to skin surrounding an eye in a human subject, comprising:
an electrolyzed saline solution having a pH ranging from about 7.4 to about 8.6,
a rheology modifier;
a silicone oil; and a buffering agent, and wherein the electrolyzed saline solution comprises reactive oxygen species of stabilized hypochlorites and stabilized superoxide radicals of O 2 * − and HO 2 * − , and wherein the reactive oxygen species in the electrolyzed saline solution mirrors reduced species and reactive oxygen species found in a known biological system; wherein the formulation has a pH in the range of about 6.7 to about 7.4.
2. The formulation of claim 1 , wherein the electrolyzed saline solution further comprises one or more of hypochlorous acid, dissolved oxygen, chlorine, hydrogen gas, hydrogen peroxide, hydrogen ions, hypochloride, ozone, activated hydrogen ions, chloride ions, hydroxides, singlet oxygen, *OCl, and *HO − .
3. The formulation of claim 1 , wherein at least one of:
the rheology modifier is a metal silicate;
the buffering agent is a phosphate buffer; and
the silicone oil is dimethicone.
4. The formulation of claim 1 , wherein the stabilized hypochlorites comprise OCl − , wherein the rheology modifier comprises sodium magnesium fluorosilicate present in an amount of about 3.25% by weight, wherein the silicone oil comprises dimethicone present in an amount of about 5% by weight, and wherein the buffering agent comprises sodium phosphate monobasic present in an amount of about 0.2% by weight.
5. The formulation of claim 1 , wherein the formulation comprises hypochlorite in an amount of about 55 ppm and sodium chloride in an amount of about 0.07% by weight.
6. A topical eye serum formulation, comprising:
an electrolyzed saline solution comprising sodium chloride in an amount of 0.07% by weight, and further comprising first, second, and third generations of reactive oxygen species (ROS), wherein the first, second, and third generations of ROS comprise O 2 * − , HO 2 * − , OCl − , HOCl, NaOCl, HClO 2 , ClO 2 , HClO 3 , HClO 4 , O 2 , O 3 , O 4 * − , 1 O, H 2 , H − , OH* − , H 2 O 2 , Cl 2 , Na + , Cl − , H, H + , and OH − ;
a rheology modifier;
a silicone oil; and
a buffering agent,
wherein the electrolyzed saline solution has a pH ranging from about 7.4 to about 8.6, and wherein the reactive oxygen species in the electrolyzed saline solution mirrors reduced species and reactive oxygen species found in a known biological system.
7. The formulation of claim 6 , wherein the formulation comprises hypochlorite in an amount of about 55 ppm, wherein the rheology modifier comprises sodium magnesium fluorosilicate present in an amount of about 3.25% by weight, wherein the silicone oil comprises dimethicone present in an amount of about 5% by weight, and wherein the buffering agent comprises sodium phosphate monobasic present in an amount of about 0.2% by weight.
8. The formulation of claim 6 , wherein the formulation has a pH in a range of about 6.7 to about 7.4.